Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02571972 · ClinicalTrials.gov registry record · Phase 2
Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.
A Phase 2 study, sponsored by Wills Eye.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT02571972: Completed Phase 2 study, sponsored by Wills Eye.
NCT02571972 is a Phase 2 study that has completed, run by Wills Eye. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02571972, a Phase 2 study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study seeks to evaluate the effect of topical aqueous suppression on the anatomic and functional response to intravitreal anti-vascular endothelial growth factor (VEGF) injections in non-responders with wet age-related macular degeneration.
Primary Outcome
Mean central subfield thickness (CST) on spectral domain optical coherence tomography (SD-OCT) on 1 visit prior to enrollment and all visits subsequent to study enrollment
Interventions
- DRUG Dorzolamide-timolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-02-01 |
| Est. Completion | 2015-12-20 |
| Phase | Phase 2 |
What the finished NCT02571972 record still lists
NCT02571972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Dorzolamide-timolol is the first listed.
NCT02571972 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02571972 about?
NCT02571972 is a clinical study titled "Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.". This study seeks to evaluate the effect of topical aqueous suppression on the anatomic and functional response to intravitreal anti-vascular endothelial growth factor (VEGF) injections in non-responders with wet age-related macular degeneration.
What is the current status of trial NCT02571972?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2015-02-01. Estimated completion is 2015-12-20.
What interventions are being tested in trial NCT02571972?
The interventions under investigation include: Dorzolamide-timolol (DRUG).
Who is sponsoring clinical trial NCT02571972?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02571972's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy